Antibody–drug conjugates have emerged as ... stages that employ payloads with distinct mechanisms of action, from immune agonist payloads to protein degrader payloads and novel cytotoxic payloads.

The wheels of the antibody-drug conjugate (ADC) juggernaut keep on turning, with Araris Biotech AG announcing a deal with a headline value of $780 million to apply its multi-payload linker technology ...

This results in T reg cell depletion and a restored antitumor immune response ... optimized antibody–drug conjugates, to bispecific antibodies and chimeric antigen receptors for cell-based ...

Elevation Oncology Inc. has nominated EO-1022 as its HER3 antibody-drug conjugate (ADC) development candidate for the treatment of solid tumors that express HER3. EO-1022 is currently advancing ...

An antibody-drug conjugate (ADC) targeting CD30 ... TNFRSF molecules and ligands are targeted on cells of the immune system to boost immune activity against a tumor cell or on tumor cells to ...

Enter the game-changer—two Pt-MSA-2 conjugates (I and II). These ingenious compounds bring together the DNA-damaging power of cisplatin and the immune-activating strength of STING agonist MSA-2.

Ltd. The partnership will leverage MediLink's TMALIN antibody-drug conjugate (ADC) platform to develop a novel LRRC15 ADC, known as ZL-6201, which includes an antibody discovered by Zai Lab.